Trials / Completed
CompletedNCT00041639
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (planned)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hMN14 (labetuzumab) |
Timeline
- Start date
- 2000-01-01
- Completion
- 2003-12-01
- First posted
- 2002-07-15
- Last updated
- 2021-08-19
Locations
10 sites across 4 countries: United States, Germany, Hungary, Netherlands
Source: ClinicalTrials.gov record NCT00041639. Inclusion in this directory is not an endorsement.